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ABSTRACT
Background: Current guidelines recommend a standard ticagrelor loading dose (LD) 
in ST-segment elevation myocardial infarction (STEMI) patients. However, 
antiplatelet therapy in STEMI patients at high risk of thrombotic events is suboptimal.
The study was conducted to validate whether vasodilator-stimulated phosphoprotein 
(VASP)-guided ticagrelor dosing individual therapy may result in more effective 
platelet inhibition and better clinical outcomes.
Methods: This trial included 374 STEMI patients with a low platelet response after 
ticagrelor LD. The patients were randomized into a control group and a VASP-guided 
group, where the ticagrelor pretreatment was individually adjusted before and after 
percutaneous coronary intervention (PCI) to obtain a VASP index < 50%. Up to 2 
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additional boluses of ticagrelor (every additional dosing was 90 mg) were prescribed 
after the first LD, and the VASP index was assessed 2 hours after each administration 
until a VASP index < 50% was obtained or up to 3 dosages (360 mg). The primary 
endpoint was major adverse cardiovascular events (MACEs) at 30 days. The 
secondary endpoints were thrombolysis in myocardial infarction (TIMI) major and 
minor bleeding.
Results: The characteristics were similar in the 2 groups. After the ticagrelor doses 
increased, the platelet reactivity index (PRI) decreased, and 98.4% of patients reached
PRI < 50% in the VASP-guided group. The adenosine concentration increased, and 
the rate of MACE was significantly lower in the VASP-guided group (10 [5.3%] vs. 
20 [10.8%], hazard ratio 2.38, 95% confidence interval 1.21–3.28, p = 0.007). There 
were no major hemorrhagic complications (0 vs. 0, p = 1.0). The rate of minor 
bleeding in the VASP-guided group was higher than that in the control group, but the 
difference was not significant (24 [12.8%] vs. 16 [8.6%], p = 0.068).
Conclusions: The incremental ticagrelor dosing strategy decreases the rate of MACE 
after PCI without increasing major and minor bleeding.
Key words: ticagrelor, vasodilator-stimulated phosphoprotein, platelet reaction 
index, ST-segment elevation myocardial infarction, primary percutaneous 
coronary intervention
INTRODUCTION
P2Y12 antagonist prasugrel and ticagrelor have been recommended for ST-
segment elevation myocardial infarction (STEMI) patients undergoing primary 
percutaneous coronary intervention (PCI) in current guidelines [1, 2]. However, some 
STEMI patients have thrombotic risk because of inadequate antithrombotic therapy 
several hours after PCI. The PLATO study [3] demonstrated that the reversible 
adenosine diphosphate (ADP) receptor antagonist ticagrelor reduced the primary 
endpoints compared to clopidogrel in acute coronary syndrome (ACS) patients 
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undergoing PCI. Ticagrelor acts directly on the P2Y12 receptor with no need for 
previous metabolic activation, which provides faster platelet inhibition than 
clopidogrel [4, 5]. In stable coronary artery disease or ACS patients, a 180-mg loading
dose (LD) of ticagrelor obviously inhibits the platelet reactivity, and most patients 
manifest adequate platelet inhibition within 1 hour below the cut-off point [4, 6]. 
However, researchers recently reported a delayed onset of ticagrelor antiplatelet 
action during the first 2 hours in STEMI patients. A higher LD of ticagrelor may be 
effective to overcome the high on-treatment platelet reactivity (HTPR) during the first
2 hours of STEMI [7]. Furthermore, we can argue that ticagrelor LD is only a daily 
dose, whereas clopidogrel LD is 4- or 8-fold the long-term daily dose. Oral ticagrelor 
is safe and well tolerated in healthy subjects at doses up to 400 mg daily [8]. 
Moreover, in the DISPERSE 2 trial, 270 mg LD of ticagrelor and a subsequent 360 
mg daily dose were not associated with a significant increase in major bleeding events
compared with standard ticagrelor administration [9]. Because the high-dose strategy 
of ticagrelor is safe, we hypothesize that incremental ticagrelor dosing may result in 
faster and more effective platelet inhibition than standard LD. Thus, in the present 
study, we compared the vasodilator-stimulated phosphoprotein (VASP)-guided 
ticagrelor dosing with standard ticagrelor LD regarding their effect on the P2Y12 
platelet receptor inhibition and clinical outcomes.
METHODS
Patient recruitment, grouping, and randomization
A single-center, prospective, randomized study was conducted in the Cardiology 
Department of Shanghai East Hospital, School of Medicine, Tongji University. The 
study protocol was in accordance with the Declaration of Helsinki and approved by 
the local ethics committee of our institution. Informed consent was obtained from all 
participants. The inclusion criterion was the need for PCI with stent implantation for 
STEMI. The exclusion criteria were platelet reactivity index (PRI) < 50% after the 
first ticagrelor LD, cardiac shock, cardiac arrest, New York Heart Association 
3
(NYHA) functional class III or IV, contraindications to antiplatelet therapy, platelet 
count < 100 × 109/L, bleeding diathesis or upper gastrointestinal hemorrhage, warfarin
or other oral anticoagulant therapy, creatinine clearance < 25 mL/min, surgery within 
1 month or scheduled in the following year, and concurrent severe illness with 
expected survival of < 1 year.
The participants were allocated into a VASP-guided group and a control group 
according to the first VASP index (PRI > 50%). Randomization was performed in a 
permuted block size of 4 using an automatically created randomization system called 
an interactive web-based response.
The present study was prospectively registered in the Chinese Clinical Trial 
Registry, a Primary Registry of the International Clinical Trial Registry Platform, 
World Health Organization (Registration no. ChiCTR-IOR-17013854). The registered
date was December 11, 2017.
Angioplasty procedure
Percutaneous coronary intervention was conducted according to international 
guidelines using a standard technique through the radial or femoral route [2]. A drug-
eluting stent (DES) was used according to the European Society of Cardiology (ESC) 
guidelines [10]. An IV bolus of unfractionated heparin (UFH; 100 IU/kg) was 
administered at the beginning of the procedure. The sheath was immediately removed 
after the procedure via the radial approach and 6 hours later via the femoral approach. 
A combination of 300 mg acetylsalicylic acid (ASA) and 180 mg ticagrelor LD was 
administered immediately after the acute myocardial infarction (AMI) diagnosis. 
Afterwards, the combination administration of 100 mg QD ASA and 90 mg BID 
ticagrelor continued for at least 1 year. Glycoprotein IIb/IIIa inhibitors (GPIs) were 
determined by interventional cardiologists. In brief, to avoid increasing bleeding and 
interaction with ticagrelor, GPI was only allowed when there was too much thrombus.
The interventional cardiologist and treating physician were not aware of the VASP 
index results or group assignment during PCI.
4
Ticagrelor modification
The VASP index was measured ≥ 2 hours after the first 180 mg LD of ticagrelor. 
All patients with a VASP index > 50% were prospectively included in the study and 
randomly assigned to the control group or VASP-guided group. In the control group, 
PCI was conducted without an additional bolus of ticagrelor. In the VASP-guided 
group, the ticagrelor pretreatment was individually adjusted before and after PCI to 
obtain a VASP index < 50%. Additional ticagrelor doses (90 mg each) were 
administered every 2 hours after the first LD until 360 mg ticagrelor was reached, i.e.,
180 mg LD and twice incremental 90-mg doses. Briefly, up to 2 additional 90 mg 
doses of ticagrelor were prescribed after the previous LD, and the VASP index was 
assessed 2 hours after each administration until a VASP index < 50% was obtained. 
Therefore, the maximum dose of ticagrelor was 360 mg. In the control group, a 
placebo was administered at each loading phase.
Blood samples
Blood samples of 10 mL for the VASP index analysis were drawn by atraumatic 
venipuncture of the antecubital vein at least 2 hours after each ticagrelor dosing. The 
initial blood drawn was discarded to avoid measuring the platelet activation induced 
by needle puncture. Blood was collected in a vacutainer (Becton Dickinson Company,
Franklin Lakes, NJ, USA) containing 3.8% trisodium citrate and filled to capacity. 
The vacutainer was inverted 3–5 times for gentle mixing and immediately sent to the 
hemostasis laboratory. In the control group, the number of times that the VASP 
samples were drawn was related to the VASP-guided group.
VASP phosphorylation analysis
The VASP index phosphorylation analysis was conducted within 2 hours of 
blood collection by an experienced investigator using platelet VASP kits (from 
BioCytex, Marseille, France) according to the manufacturer’s instructions [11]. The 
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ratio [(MFIPGE1–MFIADP+PGE1)/MFIPGE1] × 100% is expressed in this study as the PRI, 
which corresponds to a ratio of the VASP phosphorylation of activated platelets vs. 
resting platelets and is expressed as a percentage of the platelet reactivity.
Adenosine plasma concentration measurement
Blood samples (3 mL) were collected by an atraumatic venipuncture of the 
antecubital vein on admission and processed. Fresh whole blood was collected in 
tubes containing a stop solution that prevented red blood cell (RBC) uptake and 
degradation of adenosine. After centrifugation, the supernatants were deproteinized, 
and adenosine was measured using high-performance liquid chromatography [12].
Clinical endpoints
Clinical follow-up was initiated immediately after PCI and terminated 1 month 
later. The endpoints were recorded by an investigator blinded to the patients’ 
treatment status and clinical characteristics. The primary endpoint was the rate of 
major adverse cardiovascular events (MACEs) and dyspnea. MACE included target 
vessel revascularization (TVR), stent thrombosis (ST), nonfatal myocardial infarction,
and cardiovascular death at 1 month. TVR was defined as repeated PCI or coronary 
artery bypass grafting (CABG). ST was defined according to the Academic Research 
Consortium (ARC) [13]. Nonfatal myocardial infarction was defined as recurrent 
ischemic symptoms (> 20 min) and/or electrocardiographic changes after PCI with an 
increase > 20% in troponin measured after the recurrent event with at least 1 value 
above the 99th percentile of the reference range [14]. All deaths were considered 
cardiovascular deaths unless the definite reason was verified. The level of dyspnea 
was assessed using the modified Medical Research Council (MRC) scale [15]. The 
secondary endpoints were major and minor bleeding. Major bleeding was defined as 
intracranial bleeding or clinically overt bleeding associated with a 50-g/L decrease in 
hemoglobin according to the Thrombolysis in Myocardial Infarction (TIMI) criteria 
[16]. Minor bleeding was also defined according to the TIMI criteria [16]. An 
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independent clinical event committee was blinded to the treatment allocation.
Power calculation
We postulated that the average difference in MACE rate between the 2 groups 
would be 15% [14]. Therefore, for 90% power and an alpha risk of 5%, we estimated 
that 180 patients should be included in each group. We estimated that 5% of patients 
would be lost to follow-up, so the target number of included patients was 378.
Ethical approval
The study protocol was in accordance with the Declaration of Helsinki and was 
approved by the Ethics Committee of Shanghai East Hospital. Written informed 
consent was obtained from study participants.
Statistical analysis
Statistical analysis was conducted using the SPSS 17.0 software (SPSS Inc., 
Chicago, IL, USA). Continuous variables are expressed as the mean ± standard 
deviation and were tested for normality of distribution. Categorical variables are 
expressed as frequencies and percentages. Analysis of variance was used to compare 
the quantitative variables. Categorical variables were compared using the chi-squared 
test or Fisher’s exact test when the frequencies were below 5. Kaplan–Meier curves 
were used to assess the MACE-free survival. Differences between the curves were 
tested with a log-rank statistic. A P value ＜0.05 was considered significant.
RESULTS
Patient demographic, biological, and angiographic characteristics
In total, 1037 patients were included in the prospective study in the Department 
of Cardiology in the Shanghai East Hospital, School of Medicine, Tongji University 
from July 2018 to July 2019 (Fig. 1); 41 patients were excluded. PRI < 50% was 
demonstrated in 647 patients, who were considered good responders and excluded. In 
total, 390 included patients manifested PRI > 50% and were randomly divided into 
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the control group or the VASP-guided group (n = 195). Finally, 374 (95.9%) patients 
finished the 30-day follow-up (Fig. 1).
The baseline characteristics are summarized in Table 1. Demographic data and 
clinical characteristics were balanced between the 2 groups. All patients underwent 
PCI. The PCI data were also similar.
Platelet reactivity index
The mean time between the LD of ticagrelor and the blood sampling was similar 
in the two groups (116 ± 42 min vs. 124 ± 55 min, p = 0.70; Table 1). The VASP index
in the control group after ticagrelor LD was higher than that in the VASP-guided 
group, but the difference was not significant (85.4 ± 16.2 vs. 79.3 ± 13.1, p = 0.22). 
Table 2 summarizes the effect of each additional ticagrelor dosing on the PRI and the 
patient partition of VASP < 50% after each ticagrelor dosing in the two groups. In the 
VASP-guided group, after the first and second incremental ticagrelor doses, 95 
(50.5%) and 139 (74.1%) patients had a VASP index below 50%, and the average 
VASP indices after the first and second ticagrelor incremental doses were 48.5 ± 9.4%
and 36.9 ± 5.8%, respectively (p < 0.01 vs. after the LD). Eventually, 24 hours after 
LD, the incremental ticagrelor dosing gave most patients (185/188, 98.4%) a VASP 
index below 50% (the VASP index was 19.5 ± 7.3%, p < 0.01 vs. baseline). In the 
control group, only 127 (68.3%) patients reached PRI < 50% 24 hours after LD. The 
VASP index did not significantly distinguish among the 3 measurement time points 
(57.9 ± 10.0% vs. 42.8 ± 9.7% vs. 40.3 ± 9.4%, p > 0.05).
Plasma adenosine concentration
The plasma adenosine concentration in the control group increased more than that
at baseline but did not dramatically change during the 30-day follow-up, whereas in 
the VASP-guided group the adenosine concentration significantly increased when the 
ticagrelor incremental dose increased (Table 2).
Clinical endpoints
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A 30-day follow-up was completed in 374 (95.9%) patients. During follow-up, 
20 (10.8%) MACEs in the control group and 10 (5.3%) MACEs in the VASP-guided 
group occurred, which resulted in a significant difference between the two groups (p =
0.007). The distribution of cardiovascular events is summarized in Table 3. Dyspnea 
occurred more frequently in the VASP-guided group than in the control group (18.1% 
vs. 12.9%, p = 0.019). No dyspnea-intolerant patients withdrew from the study. There 
were no major hemorrhagic complications in any group. The rate of minor bleeding in
the VASP-guided group was higher than that in the control group, but the difference 
was not significant (12.8% vs. 8.6%, p = 0.068). No other side effects of ticagrelor 
(bradycardia, atrioventricular block, ventricular pause, or atrial fibrillation) were 
reported (Table 3).
Kaplan-Meier analysis
As Figure 2 shows, cumulative survival in the 2 groups was distinguished by the 
Kaplan-Meier curve. Cardiovascular event-free survival was higher in the VASP-
guided group than in the control group. The difference was significant (0 vs. 3, log 
rank 5.613, p = 0.028).
DISCUSSION
This study suggests that modified ticagrelor incremental dosing according to the 
VASP index improves the platelet reactivity and clinical outcomes in STEMI patients 
undergoing PCI. This ticagrelor incremental dosing strategy is safe and is not 
associated with an unacceptable bleeding complication rate. To the best of our 
knowledge, this is the first randomized study to demonstrate the clinical benefit of 
prospective platelet monitoring of the ticagrelor efficiency in patients undergoing 
stenting.
Incremental ticagrelor dosing increased platelet inhibition compared with 
standard 180-mg LD. Two hours after the first ticagrelor LD, approximately half of 
the patients still had high on-treatment platelet reactivity (HTPR) despite the use of 
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highly effective antiplatelet agents in both the VASP-guided group and the control 
group. Two hours after the second additional dosing, approximately two-thirds of 
patients in the VASP-guided group showed optimal platelet inhibition. At least 3 
incremental doses were required to achieve optimal platelet inhibition in most 
patients. Conversely, in a nonrandomized study by Alexopoulos et al. [17], the 
residual platelet reactivity values obtained by a double 360-mg ticagrelor LD were 
similar to the standard 180-mg LD. However, the study was purely 
pharmacodynamic, did not allow any conclusions on clinical outcomes, and had a 
small sample size (83 patients). The lack of pharmacokinetic data did not elucidate the
exact mechanisms responsible for the double LD delayed onset of action of ticagrelor.
In another study of ticagrelor escalating loading dose in STEMI patients [18], 
increasing LD regimens failed to overcome an impaired response to ticagrelor, which 
indicates a delay in drug absorption, in contrast to our study. The discrepancy may 
account for racial differences and a small sample that could not identify the clinical 
effect.
In STEMI patients, the drug absorption speed plays a dominant role during the 
action of new oral antiplatelet agents. In this spectrum of patients, nausea and 
vomiting, which resulted from an imbalance of sympathetic and vagus function, 
hemodynamic disturbance, extensive vasoconstriction, sympathetic activation, and 
morphine use significantly affected the drug onset of action. A study verified the 
effect of morphine use on the delayed antiplatelet effect [19]. However, in the present 
study, the specific type of delay in orally administered drug action was overcome by 
increasing the incremental doses of ticagrelor. The discrepancy might be attributed to 
ethics and lack of morphine use.
In the MOJITO study [20], crushed ticagrelor tablet administration in STEMI 
patients was feasible and provided earlier platelet inhibition than standard integral 
tablets. However, in the IPAAD-Tica study [21], chewed ticagrelor tablets resulted in 
significant platelet activity inhibition compared to crushed or integral tablets at 20 and
60 min. These studies indicate that the ticagrelor dosing peri-PCI is not fixed, and 
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absorption is related to platelet inhibition.
Ticagrelor is a powerful ADP receptor antagonist, and it is more effective in the 
treatment of atherothrombosis. Previous studies indicated that ticagrelor inhibited 
ADP-induced Ca2+ release compared to other P2Y12 receptor antagonists. The extra 
P2Y12 receptor inhibition of ticagrelor might be due to equilibrative nucleoside 
transporter 1 (ENT1) antagonism on platelets. ENT1 inhibition increased the 
concentration of extracellular adenosine and activated Gs-coupled adenosine A2A 
receptors [22]. Because more ticagrelor was used in the VASP-guided group, more 
ENT1 receptor was inhibited and the adenosine concentration increased, which 
resulted in more dyspnea in the VASP-guided group. In addition, ticagrelor reduced 
the rat myocardial infarct size, and the protective effect of ticagrelor depended on the 
adenosine receptor activation with downstream upregulation of endothelial nitric 
oxide synthase and cyclooxygenase (COX)2 activity [23]. This protective effect was 
demonstrated in the CvLPRIT-CMR study [24]; ticagrelor was associated with a 
smaller infarct size and lower microvascular obstruction than clopidogrel for STEMI.
The MACE discrepancies in similar Unites States and European studies occurred
due to the following: 1) Asian ethnic characteristics: in the PLATO sub-study of Asian
patients [25], the overall cardiovascular event rates were higher in Asians, and the 
primary efficacy endpoint was 12.0% in the ticagrelor group. Southeast Asians were 
more prone to develop MACEs than East Asians. 2) Clinical characteristics: In the 
present study, the percentages of hypertension, diabetes, and dyslipidemia were 46%, 
48%, and 48%, respectively. 3) The relatively small sample size in our study. Only 
68.3% of the patients in the control group had a VASP index < 50% 24 h after the first
ticagrelor loading dose. In a prospective, multicenter observational study of ACS 
patients undergoing PCI, the platelet reactivity determined by the VASP index was 
associated with and predicted the occurrence of definite acute stent thrombosis [26].
We observed no bleeding increase in the VASP-guided group despite the use of 
high ticagrelor incremental dosage, possibly because the platelet monitoring stratifies 
ticagrelor dosing according to the individual response. This individualization 
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prevented high doses of ticagrelor in patients with good responses. These results are 
consistent with a meta-analysis in which ticagrelor decreased the MACE risk and 
stent thrombosis without causing more bleeding events than clopidogrel in STEMI 
patients undergoing PCI [27]. A PLATO trial sub-study showed that only major 
bleeding was associated with a marked increase in short-term mortality [28]. 
However, the incidence of major bleeding was not higher with the ticagrelor treatment
in the PLATO trial (11.6% vs. 11.2%) [3]. Accordingly, in a retrospective cohort study
of the nationwide Chinese population, the incidence of major bleeding was 
comparable between ticagrelor and clopidogrel (3.2% vs. 4.1%) [29]. In a large 
retrospective study of real-world Chinese patients with ACS treated by PCI, ticagrelor
increased all bleeding in patients with moderate to high bleeding risk (4.8% vs. 1.3%) 
but did not increase bleeding in subjects with low bleeding risk (1.5% vs. 0.8%) [30]. 
In the present study, there was no major bleeding in either group, possibly due to the 
low bleeding risk in patients (who were relatively young, with more hypertension, 
diabetes, and dyslipidemia) in our study and the limited sample size. More minor 
bleeding was observed in the VASP-guided group, although the difference was not 
significant. The reason might have been the incremental ticagrelor dosing, which was 
used to decrease the PRP < 50%. However, the clinical outcome was safe for two 
reasons: 1) rigorous platelet activity monitoring and 2) East Asian patient inherited 
characteristics in the local Chinese population study.
In a prospective study in patients undergoing PCI, Bonello et al. [11] 
demonstrated that a 50% cutoff value of the VASP index could predict MACEs during
a 6-month follow-up. Later, the VASP index was used to adjust clopidogrel LD to 
decrease the MACE in clopidogrel-resistant patients [31]. In our previous study [32], 
modified clopidogrel maintenance doses according to the VASP index improved the 
clinical outcome in patients with clopidogrel resistance. In addition, we tailored the 
clopidogrel LD according to the VASP index to attenuate the clopidogrel resistance in 
carriers of ABCB1 mutant allele in patients undergoing PCI [33]. Because both 
ticagrelor and clopidogrel are adenosine P2Y12 receptor blockers, we preferred the 
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50% VASP index as the cutoff point.
Finally, the cost effectiveness of the proposed regimen was not evaluated in the 
present study because this was not the objective of the study. In fact, platelet function-
guided antiplatelet therapy has been shown to be superior to fixed dosing on 
clopidogrel or ticagrelor administration [34]. In the study, the costs were calculated 
per 1000 patients. VerifyNow P2Y12 assay testing was used to evaluate the platelet 
activity. The results show that the assessment of residual platelet reactivity with 
P2Y12 measurement was a cost-effective strategy to reduce financial burden 
compared to the routine administration of more expensive antiplatelet agents. Based 
on these results, it may be beneficial to guide ticagrelor dosing peri-PCI according to 
the VASP index. Nevertheless, the cost effectiveness must be analyzed in the future.
Limitations of the study
There were several limitations in the present study. The first limitation was the 
relatively small sample size, which only included 374 patients. Although we recruited 
more than 1000 patients at the beginning of the study, approximately two-thirds 
manifested good response to ticagrelor and were excluded, so only 374 patients 
finished the 30-day follow-up. According to the statistical power calculation, the 
target number of included patients was 378. Nevertheless, the present patient number 
met the statistical testing power and made a significant difference between the two 
groups. The second limitation was that all large, randomized trials to investigate 
platelet function-guided antiplatelet therapy failed to prove superiority. Only the 
TROPICAL-ACS [35] study showed that the platelet function-guided de-escalation 
was noninferior to a standard regimen. The findings of this trial warrant further 
investigation in a larger population of patients.
CONCLUSIONS
The VASP-guided individual ticagrelor incremental dosing strategy improves the 
clinical outcomes after PCI without increasing major and minor bleeding.
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Table 1. Baseline characteristics.
Characteristics Control group (n = 186) VASP-guided group (n = 188) P
Age [year] 65.3 ± 9.8 64.6 ± 10.2 0.82 
18
Men 104 (55.9%) 98 (52.1%) 0.79 
BMI [kg/m2] 26.3 ± 5.1 27.4 ± 8.2 0.54 
Myocardial infarction history 32 (17.3%) 36 (19.2%) 0.91 
CABG history 1 (0.5%) 3 (1.6%) 0.10 
Cardiovascular risk factors:
Hypertension 79 (42.7%) 94 (50.1%) 0.69 
Diabetes mellitus 93 (50.0%) 88 (46.8%) 0.48 
Dyslipidemia 92 (49.3%) 89 (47.2%) 0.64 
Current smoking 109 (58.6%) 100 (53.1%) 0.77 
Family history of CAD 30 (16.3%) 43 (22.7%) 0.28 
Treatment on admission:
ASA 174 (93.6%) 180 (95.7%) 0.7 
Beta-blocker 90 (48.6%) 95 (50.5%) 0.93 
ACEI or ARB 137 (73.5%) 141 (75.2%) 0.87 
Calcium antagonist 27 (14.3%) 24 (12.6%) 0.72 
Statin 186 (100%) 188 (100%) 1.00 
Morphine use 65 (35%) 56 (30%) 0.65
GPI 15 (8.2%) 15 (8.0%) 0.89
LVEF [%] 56.8 ± 12.4 54.3 ± 13.6 0.55 
PCI procedure:
Femoral artery 88 (47.5%) 96 (51.3%) 0.69 
Number of diseased vessels 2.3 ± 0.8 2.2 ± 1.5 0.48 
Number of treated vessels 1.8 ± 0.9 1.5 ± 0.4 0.65 
    Drug eluting stent 186 (100%) 188 (100%) 0.91
Stent length per patient [mm] 31.2 ± 2.8 29.5 ± 4.3 0.58
Average stent width [mm] 2.9 ± 0.8 3.1 ± 1.5 0.73 
Number of stents per patient 1.8 ± 0.6 2.2 ± 1.3 0. 13 
LAD 109 (58.6%) 94 (50.0%) 0.16 
LCX 23 (12.4%) 37 (19.7%) 0.25
RCA 54 (29.0%) 57 (30.3%) 0.88
Biology:
VASP before PCI [%] 85.4 ± 16.2 79.3 ± 13.1 0.22
Time between hospital admission and first LD [min]42.8 ± 10.5 44.1 ± 11.2
0.70
Time between the first LD and blood sampling 116 ± 42 124 ± 55
0.93
Hemoglobin [g/L] 13.9 ± 5.2 13.2 ± 2.8 0.84 
Platelets [109/L] 189 ± 27 201 ± 56 0.49 
Creatinine [mg/dL] 0.77 ± 0.21 0.79 ± 0.36 0.53 
Fibrinogen [g/L] 3.5 ± 1.4 3.8 ± 2.1 0.12
ASA — acetylsalicylic acid; ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin 
receptor blocker; BMI — body mass index; CABG — coronary artery bypass grafting; CAD — 
coronary artery disease; GPI — glycoprotein IIb/IIIa inhibitors; LAD — left anterior descending; LCX 
19
— left circumflex; LD — loading dose; LVEF — left ventricular ejection fraction; PCI — 
percutaneous coronary intervention; RCA — right coronary artery; VASP — vasodilator-stimulated 
phosphoprotein
Table 2. Continuous vasodilator-stimulated phosphoprotein (VASP) index, patient 
partition of VASP < 50%, and adenosine concentration after each ticagrelor loading 
dose.
Groups and variables VASP0 VASP1 VASP2 VASP3 P
Control group (n = 186)
VASP index [%] 85.4 ± 16.2 57.9 ± 10.0 42.8 ± 9.7 40.3 ± 9.4 > 0.05
Patients with VASP index < 50% 0 (0%) 90 (48.3%) 110 (59.3%) 127 (68.3%) > 
0.05
Adenosine [µg/L] 62.6 ± 11.7 98.4 ± 17.5 108.4 ± 14.1 116 ± 18.5 > 0.05
VASP-guided group (n = 188)
VASP index [%] 79.3 ± 13.1 48.5 ± 9.4 36.9 ± 5.8 19.5 ± 7.3 < 0.01
Patients with VASP index < 50% 0 (0%) 95 (50.5%) 139 (74.1%) 185 (98.4%) < 
0.01
Adenosine [µg/L] 64.3 ± 10.5 125.6 ± 19.7 147.2 ± 15.8 185 ± 16.6 < 0.01
VASP 0–3 — VASP index before the percutaneous coronary intervention baseline measurement, 2 
hours after the first additional dosing measurement, 2 hours after the second additional dosing 
measurement, and 24 hours after the percutaneous coronary intervention measurement
Table 3. Primary and secondary endpoints during the 1-month follow-up.
Endpoints Control group (n = 186) VASP-guided group (n = 188) P
Target vessel revascularization 8 (4.3%) 5 (2.7%)
0.045
Stent thrombosis at 1 month 3 (1.6%) 1 (0.5%)
0.032
Definite 2 (1.0%) 1 (0.5%)
Probable 1 (0.5%) 0 (0%)
Possible 0 (0%) 0 (0%)
Nonfatal myocardial infarction 6 (3.2%) 4 (2.1%)
0.033
Cardiac death 3 (1.6%) 0 (0%) 0.021
20
All MACE 20 (10.8%) 10 (5.3%) 0.007
Dyspnea 24 (12.9%) 34 (18.1%) 0.019
Major bleeding 0 (0%) 0 (0%) 1.0
Minor bleeding 16 (8.6%) 24 (12.8%) 0.068
MACE — major adverse cardiac events
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Figure 1. Study design chart; MACE — major adverse cardiac events; PCI — 
percutaneous coronary intervention; STEMI — ST segment elevation myocardial 
infarction; VASP — vasodilator-stimulated phosphoprotein.
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